01 /What the axis is
The hypothalamic pituitary axis is the central regulatory loop between the hypothalamus (a region of the brain), the anterior and posterior pituitary glands (a small organ at the base of the brain), and the peripheral endocrine glands they signal to. It is one of the most studied regulatory systems in biology and the framework that most growth hormone, stress response, and reproductive research is built on.
The pituitary is sometimes called the master gland because its hormones drive the release of hormones from peripheral glands (thyroid, adrenals, gonads). The hypothalamus drives the pituitary. So strictly speaking, the hypothalamus is the master, and the axis as a whole is the regulatory system.
02 /Hypothalamic releasing and inhibiting hormones
The hypothalamus produces small peptides (typically 3 to 44 amino acids) that travel through a portal blood system to the anterior pituitary and either stimulate or inhibit the release of pituitary hormones. The major releasing peptides include GHRH (growth hormone releasing hormone), CRH (corticotropin releasing hormone), TRH (thyrotropin releasing hormone), and GnRH (gonadotropin releasing hormone). The major inhibiting signals include the peptide somatostatin (inhibits growth hormone) and the monoamine dopamine (inhibits prolactin).
The Apothify library covers GHRH analogs (Sermorelin, Modified GRF 1-29 / CJC 1295 no DAC, CJC 1295 with DAC, Tesamorelin). It does not list the other major releasing hormones because they are not commonly sold as research peptides in the consumer or biohacker categories.
03 /Anterior pituitary hormones
The anterior pituitary produces growth hormone (GH), adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), luteinizing hormone (LH), and prolactin. Each is produced by a different cell type (somatotroph for GH, corticotroph for ACTH, etc.) and each is regulated by a different hypothalamic input.
Growth hormone is the most relevant for the Apothify library. The library's GHRH analogs and ghrelin receptor agonists both target the somatotroph cell, the GHRH analogs through the GHRH receptor and the ghrelin receptor agonists through the GHS-R1a receptor (also expressed on somatotrophs).
04 /The ghrelin pathway as a parallel input
Ghrelin is a 28 amino acid gut peptide produced primarily in the stomach. It binds the ghrelin receptor in the anterior pituitary and triggers growth hormone release through a pathway parallel to GHRH. This is the second input to the somatotroph, and it is the target of the GHRP family (Ipamorelin, GHRP 2, GHRP 6, Hexarelin) and the small molecule MK 677.
Why two parallel pathways converge on the same cell is a research question in its own right. The current understanding is that the parallel inputs allow for fine grained control of growth hormone release timing and amplitude in different physiological states.
05 /Posterior pituitary hormones
The posterior pituitary releases oxytocin and vasopressin (also called antidiuretic hormone, ADH). Both are nonapeptides (9 amino acids), both are produced in hypothalamic neurons whose axons terminate in the posterior pituitary, and both are released directly into systemic circulation.
Apothify lists Oxytocin and Vasopressin in the sleep and stress category. The interaction matrix flags them as caution when paired because of their structural similarity and receptor crosstalk.
06 /Downstream peripheral hormones
Each anterior pituitary hormone drives the release of a peripheral hormone. ACTH drives cortisol from the adrenal cortex. TSH drives thyroid hormones from the thyroid. FSH and LH drive sex steroids from the gonads. Growth hormone drives IGF-1 from the liver.
The Apothify library lists IGF-1 LR3 as a research entry. It is the only downstream peripheral hormone represented in the library; the others (cortisol, thyroid hormones, sex steroids) are not peptides and are not in scope.
07 /Negative feedback loops
Each axis includes negative feedback loops. High cortisol inhibits CRH and ACTH (cortisol feeds back on the hypothalamus and pituitary). High IGF-1 inhibits GHRH and growth hormone (IGF-1 feeds back). High thyroid hormones inhibit TRH and TSH.
Negative feedback is why exogenous administration of any axis hormone (or a research analog) eventually shifts the entire axis. Research with axis active compounds must account for the feedback timeline.
08 /Where the Apothify library fits
Growth hormone axis: GHRH analogs (Sermorelin, CJC 1295 family, Tesamorelin), ghrelin receptor agonists (Ipamorelin, GHRP 1/2/6, Hexarelin, Alexamorelin, MK 677, Tabimorelin, Anamorelin), and IGF-1 LR3 as the downstream component.
Reproductive axis: Kisspeptin 10 (an upstream regulator of GnRH release) and Galanin (a neuropeptide that interacts with the HPG axis).
Posterior pituitary: Oxytocin, Vasopressin.
Other axis components (CRH, ACTH, TRH, TSH, FSH, LH) are not in the Apothify library because they are not commonly sold as research peptides for the consumer or biohacker categories. Researchers needing them work through specialized biochemistry suppliers.
09 /How to read this in the peptide pages
The growth hormone research category page lists the major axis active compounds. Each peptide page identifies which receptor the compound engages. The compare tool flags interactions; same receptor compounds are redundant, different receptor compounds (one GHRH analog plus one GHRP) are synergistic.
The growth hormone secretagogues vs GHRH guide goes deeper into the two parallel input distinction. The GHRH and GHRP pairing explained guide covers the canonical research stack.
10 /Why this matters for protocol design
Most research protocols target one axis component. Combinations that span the axis (e.g., a GHRH analog plus IGF-1 LR3) are studied less commonly because the downstream feedback effects complicate interpretation. The published research is heaviest on the immediate upstream components (GHRH analogs and GHRPs); the downstream IGF-1 work is more specialized.
Understanding which axis component each peptide engages is the first step in designing a protocol that produces interpretable research signal.
